Morepen Laboratories Ltd Sees Exceptional Volume Surge Amidst Strong Price Gains

Exceptional Trading Volumes and Price Performance

On 5 August 2026, Morepen Laboratories Ltd (symbol: MOREPENLAB) recorded a staggering total traded volume of 5.07 crore shares, translating to a total traded value of approximately ₹385.24 crores. This volume places the stock among the most actively traded equities on the day, reflecting significant market participation. The stock opened at ₹73.24, marking a gap-up of 9.67% from the previous close of ₹69.18, and touched an intraday high of ₹78.25, representing a 13.1% rise from the prior day’s close. The last traded price (LTP) stood at ₹74.34 as of 09:44:47 IST, maintaining a strong upward momentum.

The stock’s performance notably outpaced the Pharmaceuticals & Biotechnology sector, which declined by 0.47% on the same day, and also surpassed the Sensex’s marginal gain of 0.05%. Morepen Laboratories has been on a consistent upward trajectory, registering gains for four consecutive days and delivering a cumulative return of 35.29% over this period. This sustained rally underscores robust investor confidence and positive sentiment surrounding the company.

Technical Indicators and Moving Averages

Morepen Laboratories is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests a strong bullish trend and potential for further upside. The stock also hit a new 52-week high of ₹76.38 during intraday trading, reinforcing its breakout status.

Interestingly, despite the high volume, the stock traded within a narrow range of ₹0.57, indicating that most of the volume was concentrated near the lower end of the day’s price band. The weighted average price suggests that significant trading occurred close to the day’s low, which may imply accumulation by institutional investors or large traders seeking to build positions at relatively favourable prices.

Rising Investor Participation and Delivery Volumes

Investor participation has surged dramatically, as evidenced by the delivery volume on 4 August 2026, which stood at 2.25 crore shares. This figure represents an extraordinary increase of 1189.93% compared to the five-day average delivery volume, signalling strong accumulation by long-term investors rather than speculative intraday trading. Such a spike in delivery volumes often precedes sustained price appreciation, as it reflects genuine buying interest and confidence in the company’s fundamentals.

Fundamental and Market Capitalisation Context

Morepen Laboratories operates within the Pharmaceuticals & Biotechnology industry and is classified as a small-cap company with a market capitalisation of ₹3,792 crores. The company’s mojo score currently stands at 64.0, reflecting a Hold rating, an upgrade from its previous Sell grade as of 3 August 2026. This upgrade indicates an improvement in the company’s financial metrics, trend assessments, and overall quality grades, as evaluated by MarketsMOJO’s proprietary scoring system.

Liquidity and Trading Viability

The stock’s liquidity profile is robust, with the ability to support trade sizes of up to ₹2.29 crores based on 2% of the five-day average traded value. This level of liquidity is favourable for institutional investors and large traders seeking to enter or exit positions without causing significant price disruption. The combination of high volume, strong price action, and adequate liquidity makes Morepen Laboratories an attractive candidate for active trading and portfolio inclusion.

Accumulation/Distribution Signals and Market Sentiment

The surge in delivery volumes alongside the price appreciation suggests a clear accumulation phase. Market participants appear to be absorbing available shares, which is often a precursor to further price gains. The narrow intraday trading range coupled with volume concentration near the lower price band supports the thesis of institutional accumulation rather than distribution or profit booking.

Moreover, the upgrade in mojo grade from Sell to Hold reflects an improved outlook on the company’s fundamentals and technical positioning. While the stock remains a Hold, the positive momentum and volume dynamics could prompt further upgrades if the trend sustains and financial results meet or exceed expectations.

Outlook and Investor Considerations

Investors should note that while Morepen Laboratories has demonstrated strong volume and price action, the stock remains classified as a small-cap with inherent volatility risks. The recent mojo grade upgrade to Hold suggests cautious optimism, but investors are advised to monitor upcoming quarterly results and sector developments closely.

Given the stock’s outperformance relative to its sector and the Sensex, alongside the significant accumulation signals, Morepen Laboratories could be poised for further gains if it sustains its current momentum. However, the narrow intraday trading range and volume concentration near lows also warrant vigilance for potential profit-taking or volatility spikes.

Summary

Morepen Laboratories Ltd’s exceptional trading volume of over 5 crore shares and a price gain of nearly 7% on 5 August 2026 highlight a strong resurgence in investor interest. The stock’s technical strength, rising delivery volumes, and mojo grade upgrade collectively point to an accumulation phase that may support further upside. While liquidity and market participation are favourable, investors should balance the positive signals with the inherent risks of small-cap stocks and evolving sector dynamics.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →